NAFLD 臨床治療パスウェイ (NCCP)
VA プライマリケアにおける NAFLD 臨床ケア経路の有効性のテスト
Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer. Obesity and diabetes, conditions that are very common among Veterans are the main risk factors for NAFLD. Therefore, the burden of NAFLD and its complications among Veterans is substantial. However, most VA patients with NAFLD are undiagnosed and untreated, and their care is not consistent with practice guidelines. The NAFLD Clinical Care Pathway (NCCP) intervention seeks to close this major gap in the care of Veterans by automatically identifying patients at risk of NAFLD, calculating their risk scores of having severe NAFLD, and educating the primary care providers on the diagnosis and treatment of NAFLD. This clinical trial will test the benefit of this NCCP intervention against usual care in increasing the rates of NAFLD diagnosis as well as referral to and enrollment in appropriate treatment. The study will also identify barriers and promotors of future NCCP implementation.
調査の概要
詳細な説明
Background: In the United States, non-alcoholic fatty liver disease (NAFLD) affects 25-30% of adults and has become a leading cause of chronic liver disease including cirrhosis and liver cancer. The burden of NAFLD and its complications among patients in the Department of Veterans Affairs (VA) is increasing. Most complications occur among patients with advanced hepatic fibrosis. Treatment (e.g., weight loss) improves patients' outcomes.
Significance: The investigator's data indicate that most VA patients with NAFLD are undiagnosed and untreated. There is an urgent need to address this major gap in care. Most people with NAFLD are seen in primary care settings. The NAFLD Clinical Care Pathway (NCCP) is a multistep, algorithmic process that entails identification of patients at risk through an e-trigger (Step 1), targeted history and lab testing (Step 2), noninvasive testing for hepatic fibrosis using FIB-4 (Step 3), elective additional fibrosis testing with Fibroscan for those with indeterminate FIB-4 (Step 4), and subsequent recommended management. The NCCP has face and content validity based on consensus of multiple stakeholders including VA clinicians, and high efficacy in the investigator's preliminary data. The investigators propose to adapt the multicomponent NCCP intervention for use in VA primary care and prospectively test its effectiveness for identification and severity stratification of patients with NAFLD. The investigator's approach is consistent with VA strategic priorities to implement a more "Veteran-centered" approach that improves access to care.
Innovation & Impact: This is the first study to examine the effectiveness of any NAFLD clinical care pathway in a VA primary care practice. The design is a cluster-randomized controlled trial with randomization at the level of Patient Aligned Care Teams (PACTs) in primary care, and a state-of-the-art technique to diagnose NAFLD and stage the severity of hepatic fibrosis. The investigator's formative and summative evaluation will provide key information about the feasibility, acceptability and determinants of implementation. The NCCP intervention is a paradigm shift in NAFLD care from haphazard and sporadic care into a systematic, equitable, and evidence-based approach.
Specific Aims: Aim 1. Conduct a formative evaluation to assess feasibility and acceptability of the NCCP among patients and providers; adapt the NCCP for prospective testing based on feedback. Aim 2. Examine the effectiveness of the NCCP intervention compared to usual care in improving NAFLD care processes and patient outcomes. Aim 3. Conduct a summative evaluation to identify patient and provider characteristics associated with effectiveness of NCCP and to assess future implementation. The investigator's hypothesis is that NCCP when adapted to Patient Aligned Care Teams (PACTs) in VA primary care considerably increases the identification of patients with NAFLD and those with high-risk NAFLD, and results in an increase in guideline-concordant management.
Methodology: The study will be conducted in primary care settings in a single large VA Medical Center. The investigators will conduct patient interviews and focus groups with PACTs to inform adaption of the NCCP. The investigators will then conduct a cluster-randomized trial of 16 PACTs in primary care to compare the effectiveness of NCCP to usual care in improving NAFLD care, with PACTs as unit of randomization and patients as the unit of analysis. The multicomponent intervention includes an e-trigger to identify patients eligible for NAFLD screening and calculate fibrosis scores, a structured provider education on NAFLD management and treatment recommendations, and coordination by an inter-professional team. The primary outcome will be a composite binary variable consisting of NAFLD diagnosis and risk stratification. Secondary outcomes include referral to a weight loss program, referral of patients with advanced fibrosis to hepatology specialty care, and enrollment among those referred to weight loss and hepatology specialty care. Summative evaluation will inform future implementation.
Next Steps/Implementation: The investigators study will provide information needed to support future projects to implement the NCCP in VA primary care settings. The study will also lay the foundation for a subsequent project to examine the adopted intervention's effect on weight loss and NAFLD biomarkers in patients with high-risk NAFLD.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Hashem B El-Serag, MD MPH
- 電話番号:(713) 794-8640
- メール:Hashem.El-Serag@va.gov
研究連絡先のバックアップ
- 名前:Kyler Godwin, PhD MPH BS
- 電話番号:(713) 440-4672
- メール:kyler.godwin@va.gov
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030-4211
- 募集
- Michael E. DeBakey VA Medical Center, Houston, TX
-
コンタクト:
- Hashem B El-Serag, MD MPH
- 電話番号:(713) 794-8640
- メール:Hashem.El-Serag@va.gov
-
コンタクト:
- Kyler Godwin, PhD MPH BS
- 電話番号:(713) 440-4672
- メール:kyler.godwin@va.gov
-
主任研究者:
- Hashem B. El-Serag, MD MPH
-
副調査官:
- Kyler Godwin, PhD MPH BS
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Patient Aligned Care Teams (PACT) at the Michael E. DeBakey VA Medical Center
Exclusion Criteria:
-
The investigators will exclude PACTs with unstable leadership (i.e., pending departure, vacancy) at time of randomization
-
PACTs participating in the focus groups in Aim 1 will be excluded in Aim 2 to avoid cross contamination
-
PACTs meeting the following criteria will be excluded from randomization in Aim 2:
- PACTs who do not treat NAFLD
- PACTs not located at the main hospital
- PACTs with less than 100 visits within 3 months
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:E-trigger
The NCCP Intervention is made up of multiple components. The investigators will start by applying the e-trigger and assessing the FIB-4 score, and then will train and educate PACT personnel on managing patients with positive triggers, including making treatment recommendations in collaboration with an inter-professional team. The e-trigger will be generated every three months. |
The NCCP Intervention is multicomponent. First, the investigators will apply the e-trigger and calculate FIB-4, and second, will educate and train PACT personnel on how to deal with trigger positive patients as well as make treatment recommendations within an inter-professional team. The e-trigger will be generated every 3 months. The effectiveness of the trigger will be assessed using the outcomes previously mentioned. |
|
介入なし:Usual care
The control group will receive no additional training or education. PACTs will provide usual care. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
NAFLD Diagnosis and risk stratification
時間枠:Baseline, 6 months
|
The investigators will use chart reviews to extract unstructured data regarding the primary outcome measure: existence of electronic health record (EHR) progress note documenting a new NAFLD diagnosis AND complete risk stratification of NAFLD (i.e., fibrosis). The investigators will use our validated process to guide uniform abstraction and classification. |
Baseline, 6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fibroscan Test
時間枠:Baseline, 6 & 12 months
|
The investigators will extract from the electronic health record (EHR) if a patient had a fibroscan test. |
Baseline, 6 & 12 months
|
|
Referral to hepatology
時間枠:Baseline, 6 and 12 months
|
The investigators will extract from the electronic health record (EHR) if a patient was referred to a hepatology clinic. |
Baseline, 6 and 12 months
|
|
Hepatology Clinic Visit
時間枠:Baseline, 6 and 12 months
|
The investigators will extract from the electronic health record (EHR) if a patient was seen in a hepatology clinic. |
Baseline, 6 and 12 months
|
|
NAFLD discussion
時間枠:6 and 12 months
|
The investigators will extract from the patient chart if the provider documented a discussion about NAFLD with the patient. |
6 and 12 months
|
|
Referral to weight loss services
時間枠:Baseline, 6 and 12 months
|
The investigators will extract from the electronic health record (EHR) if a patient was referred to weight loss services. |
Baseline, 6 and 12 months
|
|
Enrollment in weight loss services
時間枠:Baseline, 6 and 12 months
|
The investigators will extract from the electronic health record (EHR) if a patient was referred to weight loss services. |
Baseline, 6 and 12 months
|
協力者と研究者
捜査官
- 主任研究者:Hashem B. El-Serag, MD MPH、Michael E. DeBakey VA Medical Center, Houston, TX
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- IIR 22-071
- 5I01HX003655-03 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The investigators will not share data at the individual level, only in aggregate. No data will leave the VA.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。